Literature DB >> 12964000

Resveratrol suppresses growth of Ishikawa cells through down-regulation of EGF.

Masanori Kaneuchi1, Masahiro Sasaki, Yuichiro Tanaka, Ritsu Yamamoto, Noriaki Sakuragi, Rajvir Dahiya.   

Abstract

Resveratrol and other polyphenols have anti-carcinogenic and anti-tumorigenic activities in various carcinomas. However, such studies are limited in endometrial cancer. We hypothesize that resveratrol suppresses cancer growth through modulation of cell cycle and cell growth regulatory genes. To test this hypothesis, we treated endometrial cancer cells (Ishikawa cell line) with resveratrol (1, 10, 50 and 100 micro M) for 1, 3, 5 and 7 days, and analyzed for growth signal genes (EGF and VEGF), cell cycle regulatory genes (p53 and p21), and apoptosis-related genes (bcl-2 and bax). Results of these experiments demonstrate that after resveratrol treatment, the growth of Ishikawa cells was inhibited in a dose dependent manner. The gene and protein expression data suggest that resveratrol treatment significantly decreased EGF, whereas VEGF was up-regulated in Ishiwaka cell lines. Interestingly, protein expressions of p21 and Bax were decreased, even though their mRNA expressions did not show significant changes. The present study suggests that resveratrol can suppress proliferation of Ishikawa cells through down-regulation of EGF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12964000

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells.

Authors:  Nicolas G Azios; Suranganie F Dharmawardhane
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

2.  Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat.

Authors:  Suresh Varma Penumathsa; Mahesh Thirunavukkarasu; Srikanth Koneru; Bela Juhasz; Lijun Zhan; Rima Pant; Venugopal P Menon; Hajime Otani; Nilanjana Maulik
Journal:  J Mol Cell Cardiol       Date:  2006-12-26       Impact factor: 5.000

3.  Pro-apoptotic versus anti-apoptotic properties of dietary resveratrol on tumoral and normal cardiac cells.

Authors:  Mauhamad Baarine; Sijo Joseph Thandapilly; Xavier Lieben Louis; Frédéric Mazué; Liping Yu; Dominique Delmas; Thomas Netticadan; Gérard Lizard; Norbert Latruffe
Journal:  Genes Nutr       Date:  2011-05-04       Impact factor: 5.523

Review 4.  Potential Therapeutic Targets of Resveratrol, a Plant Polyphenol, and Its Role in the Therapy of Various Types of Cancer.

Authors:  Saleh A Almatroodi; Mohammed A Alsahli; Abdullah S M Aljohani; Fahad A Alhumaydhi; Ali Yousif Babiker; Amjad Ali Khan; Arshad Husain Rahmani
Journal:  Molecules       Date:  2022-04-21       Impact factor: 4.927

Review 5.  Resveratrol: A potential challenger against gastric cancer.

Authors:  Aida Zulueta; Anna Caretti; Paola Signorelli; Riccardo Ghidoni
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

6.  Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells.

Authors:  Emilie Sexton; Céline Van Themsche; Kim LeBlanc; Sophie Parent; Pascal Lemoine; Eric Asselin
Journal:  Mol Cancer       Date:  2006-10-17       Impact factor: 27.401

7.  Analysis of origin and protein-protein interaction maps suggests distinct oncogenic role of nuclear EGFR during cancer evolution.

Authors:  Ainur Sharip; Diyora Abdukhakimova; Xiao Wang; Alexey Kim; Yevgeniy Kim; Aigul Sharip; Askarbek Orakov; Lixia Miao; Qinglei Sun; Yue Chen; Zhenbang Chen; Yingqiu Xie
Journal:  J Cancer       Date:  2017-03-12       Impact factor: 4.207

8.  Autophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cells.

Authors:  Tomohiko Fukuda; Katsutoshi Oda; Osamu Wada-Hiraike; Kenbun Sone; Kanako Inaba; Yuji Ikeda; Chinami Makii; Aki Miyasaka; Tomoko Kashiyama; Michihiro Tanikawa; Takahide Arimoto; Tetsu Yano; Kei Kawana; Yutaka Osuga; Tomoyuki Fujii
Journal:  Oncol Lett       Date:  2016-08-08       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.